pinacolyl tert-butyl ether | 25246-78-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: pinacolyl tert-butyl ether
• 英文别名: 3-tert-Butoxy-2,2-dimethylbutane；2,2-dimethyl-3-[(2-methylpropan-2-yl)oxy]butane
• CAS: 25246-78-0
• 化学式: C₁₀H₂₂O
• 分子量: 158.284
• InChiKey: CKTYVJPPLCJXPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,3-二甲基-1-丁烯 、 叔丁醇 在 sodium hydroxide 、 sodium tetrahydroborate 、 mercury(II) trifluoroacetate 作用下， 生成 pinacolyl tert-butyl ether
  参考文献：
  名称：

  Solvomercuration-demercuration. 12. The solvomercuration-demercuration of olefins in alcohol solvents with mercuric trifluoroacetate - an ether synthesis of wide generality

  摘要：

  DOI：

  10.1021/jo00208a005

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20160376238A1

  公开（公告）日：2016-12-29

  The invention provides compounds of formula (I): wherein, A, C, D, X, and Y have any of the values defined in the specification, and salts thereof. The compounds are SIRT2 inhibitors and are useful for treating SIRT2 associated conditions.

  这项发明提供了式（I）的化合物： 其中，A、C、D、X 和 Y 可以取规范中定义的任何值，以及它们的盐。这些化合物是SIRT2抑制剂，可用于治疗与SIRT2相关的疾病。
• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20150266911A1

  公开（公告）日：2015-09-24

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  目前的技术是针对前药和组合物的，用于治疗包括甲基苯丙胺或甲基苯丙胺衍生物的至少与醇、胺、羧酸、硫醇或其衍生物结合的各种疾病和/或紊乱。在某些实施例中，这些结合物还包括至少一个连接剂。该技术还涉及合成甲基苯丙胺或甲基苯丙胺衍生物，结合至少一个醇、胺、羧酸、硫醇或其衍生物或其组合的方法。
• ORGANIC COMPOUNDS AND THEIR USES
  申请人：Brandl Trixl

  公开号：US20100204159A1

  公开（公告）日：2010-08-12

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

  本申请描述了对人类疾病的治疗、预防和/或改善有用的有机化合物。
• UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
  申请人：Chao Hannguang J.

  公开号：US20080280905A1

  公开（公告）日：2008-11-13

  The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型吡啶基或苯基脲及其类似物，它们是选择性的人类P2Y1受体抑制剂。本发明还提供了各种该类药物组成物和调节P2Y1受体活性以治疗对其反应的疾病的方法。
• METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME
  申请人：Guenther Sven

  公开号：US20140243291A1

  公开（公告）日：2014-08-28

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  本技术涉及用于治疗各种疾病和/或障碍的前药和组合物，包括将哌甲酯或哌甲酯衍生物与至少一种醇，胺，羧酸，硫醇或其衍生物结合。在某些实施例中，共轭物还包括至少一个连接剂。本技术还涉及合成哌甲酯或哌甲酯衍生物与至少一种醇，胺，羧酸，硫醇或其衍生物或其组合物结合的方法。